Abstract
Involvement of LST-1 (a human liver-specific transporter, also called OATP2) as the major transporter in the uptake of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, by human liver was demonstrated. The hepatic uptake of pravastatin evaluated using human hepatocytes was Na+-independent and reached saturation with a Michaelis constant (Km) of 11.5 ± 2.2 μM. The uptake of pravastatin was temperature-dependent and was inhibited by estradiol-17β-d-glucuronide, taurocholic acid, bromosulfophthalein, and simvastatin acid, but not byp-aminohippurate. Estradiol-17β-d-glucuronide competitively inhibited pravastatin uptake with an inhibition constant comparable to theKm value for estradiol-17β-d-glucuronide transport, indicating that a common transporter mediates the transport of pravastatin and estradiol-17β-d-glucuronide in human hepatocytes. The results obtained with human hepatocytes agreed with those obtained with LST-1 expressing Xenopus oocytes. Oocytes microinjected with human liver polyadenylated mRNA showed Na+-independent uptake of pravastatin and estradiol-17β-d-glucuronide. A simultaneous injection of LST-1 antisense oligonucleotides completely abolished this uptake. Expression of LST-1 was immunohistochemically demonstrated in the human hepatocytes, but not in Hep G2 cells, which showed very low uptake of pravastatin. Therefore, LST-1 was regarded as a key molecule for pravastatin in liver-specific inhibition of cholesterol synthesis, making pravastatin accessible to the target enzyme, which would otherwise not be inhibited by this hydrophilic drug.
Footnotes
-
Send reprint requests to: Dr. Taro Tokui, Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., 2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan. E-mail:tokuit{at}shina.sankyo.co.jp
- Abbreviations:
- HMG-CoA
- 3-hydroxy-3-methylglutaryl coenzyme A
- OATP2
- organic anion transporting polypeptide 2
- LST-1
- human liver-specific organic anion transporter
- KHL
- keyhole limpet hemocyanin
- Km
- Michaelis constant
- Vmax
- maximum uptake rate
- Pdif
- nonspecific uptake clearance
- Ki
- inhibition constant
- Received October 19, 2000.
- Accepted January 2, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|